Drug Trial Radar · NCT01356498
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
Last checked: Nov 20, 2026Latest source record: Dec 2, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
151
Actual
Start
Dec 2006
Primary completion
Jan 2010
Study completion Jan 2010
Sponsor
- Lead sponsor
- Savient PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 19, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label extension phase of two double-blind, placebo-controled Phase 3 protocols evaluating PEG-uricase in the treatment of hyperuricemic subjects with symptomatic gout. The purpose of this study is to provide a continuation of treatment to subjects completing the double-blind studies and obtain long-term safety and efficacy data.
Conditions
- Gout
Interventions
pegloticaseBiological
8 mg intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Uric Acid (mg/dL)Time frame: Week 13, Week 25, Week 53, Week 101
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Kaiser Permanente Medical Center, Clinical Trials Unit
San Francisco, California
Pacific Arthritis Center Medical Group
Santa Maria, California
Agilence Arthritis & Osteoporosis Medical Center
Whittier, California
Veterans Affairs Medical Center
Washington D.C., District of Columbia
Arthritis & Rheumatic Disease Specialties
Aventura, Florida
Ocala Rheumatology Research Center
Ocala, Florida
St. Petersburg Arthritis Center
St. Petersburg, Florida
The University of Chicago
Chicago, Illinois
Graves Gilbert Clinic
Bowling Green, Kentucky
Peter A. Holt, M.D.
Baltimore, Maryland
Center for Rheumatology and Bone Research
Wheaton, Maryland
Justus J. Fiechtner, MD, PC
Lansing, Michigan
CentraCare Clinic
Saint Cloud, Minnesota
Rheumatology Associates of North Jersey
Teaneck, New Jersey
Duke University Medical Center
Durham, North Carolina
New Horizons Clinical Research
Cincinnati, Ohio
The Ohio State University
Columbus, Ohio
STAT Research, Inc.
Dayton, Ohio
David R. Mandel, MD, Inc.
Mayfield Village, Ohio
Altoona Center for Clinical Research
Duncansville, Pennsylvania
Mid Atlantic Research Assoc.
Philadelphia, Pennsylvania
Arthritis Northwest, PLLC
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.